News Release - Eli Lilly and Company
WEBMay 13, 2022 · Mounjaro will be available in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) and will come in Lilly 's well-established auto-injector pen with a pre-attached, hidden needle that patients do not need to handle or see.
FDA approves Eli Lilly’s diabetes drug Mounjaro for obesity ... - CNN
WEBNov 8, 2023 · The drug, called Mounjaro for diabetes, will be called Zepbound for weight loss, according to a news release from the FDA. Made by Eli Lilly, it’s part of a new class of drugs that includes...
Drugmaker Lilly slates another $4.5B for manufacturing and drug ...
WEB3 days ago · Eli Lilly is pouring another $4.5 billion into expanding drug manufacturing and development. The diabetes treatment maker said Wednesday that it will build a new center for advanced manufacturing and drug development a few miles from its …
Tirzepatide cuts risk of diabetes by 94% in adults with ... - CNN
WEBAug 20, 2024 · A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight...
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
WEB2 days ago · The Food and Drug Administration on Wednesday declared an end to the two-year shortage of tirzepatide, the substance in the popular weight-loss medication Zepbound and the diabetes drug Mounjaro...
News Release - Eli Lilly and Company
WEBJun 20, 2024 · Lilly does not promote or encourage use of Mounjaro ®, Zepbound ®, or any Lilly medicine outside of its FDA-approved indication. Mounjaro ® is an injectable prescription medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose).
Lilly hits record high after Mounjaro fuels forecast raise, rival data
WEBAug 8 (Reuters) - Eli Lilly (LLY.N) on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares...
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better …
WEBAug 8, 2024 · INDIANAPOLIS (AP) — Eli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit ...
WEBApr 30, 2024 · Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
Eli Lilly lifts guidance after sales of Mounjaro and Zepbound …
WEBApr 30, 2024 · Soaring sales of Eli Lilly’s hugely popular diabetes and weight loss drugs Mounjaro and Zepbound prompted the US pharmaceutical group to lift its guidance for the year and pushed its share...